PROKOP, Radim, Jana KAŠPÁRKOVÁ, Olga NOVAKOVA, María Victoria MARINI PALOMEQUE, Ana M. PIZARRO, Carmen NAVARRO-RANNINGER and Viktor BRABEC. DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand. Biochemical Pharmacology. Oxford, UK: Elsevier, 2004, vol. 67, No 6, p. 1097-109, 13 pp. ISSN 0006-2952.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand.
Name in Czech Interakce novych protinadorovych platinovych komplexu s DNA
Authors PROKOP, Radim (203 Czech Republic), Jana KAŠPÁRKOVÁ (203 Czech Republic), Olga NOVAKOVA (203 Czech Republic), María Victoria MARINI PALOMEQUE (858 Uruguay), Ana M. PIZARRO (724 Spain), Carmen NAVARRO-RANNINGER (724 Spain) and Viktor BRABEC (203 Czech Republic, guarantor).
Edition Biochemical Pharmacology, Oxford, UK, Elsevier, 2004, 0006-2952.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10610 Biophysics
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.436
RIV identification code RIV/00216224:14310/04:00029123
Organization unit Faculty of Science
UT WoS 000220333900012
Keywords in English cisplatin; platinum complexes; DNA; antitumor
Tags antitumor, cisplatin, DNA, platinum complexes
Tags International impact, Reviewed
Changed by Changed by: Mgr. María Victoria Marini Palomeque, Ph.D., učo 22912. Changed: 19/1/2009 14:32.
Abstract
The global modification of mammalian and plasmid DNAs by novel platinum compounds, trans-[PtCl(2)(NH(3))(Am)], where Am=2 -methylbutylamine or sec-butylamine was investigated in cell-free media using various biochemical and biophysical methods. These modifications were analyzed in the context of the activity of these new compounds in several tumor cell lines including those resistant to antitumor cis-diamminedichloroplatinum(II) (cisplatin). The results showed that the replacement of one amine group by 2-methylbutylamine or sec-butylamine ligand in clinically ineffective trans-diamminedichloroplatinum(II) (transplatin) resulted in a radical enhancement of its activity in tumor cell lines so that they are more cytotoxic than cisplatin and exhibited significant antitumor activity including activity in cisplatin-resistant tumor cells. Importantly, this replacement also markedly altered DNA binding mode of transplatin and reduced the efficiency of repair systems to remove the adducts of the new analogues from DNA. The results support the view that one strategy to activate trans geometry in bifunctional platinum(II) compounds including circumvention of resistance to cisplatin may consist in a chemical modification of the ineffective transplatin which results in an increased efficiency to form DNA interstrand cross-links.
Abstract (in Czech)
cz
Links
GA305/02/1552, research and development projectName: Oligonukleotidy modifikované komplexy platiny pro selektivní modulaci genové exprese; vztah k "protismyslné" strategii při vývoji nových farmak.
PrintDisplayed: 25/4/2024 06:21